Amgen managed a 9th place sport in top R&D research spending and a 14th place spot for sales in 2006. Not an overly good year for the company as it had to deal with the fallout from the increased box warning from the FDA on Aranesp and Epogen, drugs for anemia. Amgen has 17 different drug in various phases with several in multiple phases for various indications.
Phase I drugs:
AMG 221 Type 2 diabetes
AMG 317 Asthma
AMG 379 Pain
AMG 386 Cancer
AMG 403 Pain
AMG 479 Cancer
AMG 623 Systemic lupus erythematosus
AMG 655 Cancer
AMG 714 Psoriasis
AMG 745 Muscle wasting disorders
AMG 220 Crohn's Disease
AMG 557 Systemic lupus erythematosus
AMG 837 Type 2 diabetes
Apo2L/TRAIL Cancer
Phase II drugs:
AMG 102 Cancer
AMG 108 Rheumatoid arthritis
AMG 531 Chemotherapy-induced thrombocytopenia in non-small cell lung cancer and lymphoma
AMG 531 Myelodysplastic syndromes
Denosumab Rheumatoid arthritis
Palifermin Oral mucositis associated with radiation therapy and chemotherapy for solid tumors
Motesanib diphosphate* First-line breast cancer
Motesanib diphosphate* First-line non-small cell lung cancer
Motesanib diphosphate* Thyroid cancer
Cinacalcet HCI Primary hyperparathyroidism
Panitumumab Head and neck cancer AMG 102 Cancer
AMG 108 Rheumatoid arthritis
AMG 531 Chemotherapy-induced thrombocytopenia in non-small cell lung cancer and lymphoma
AMG 531 Myelodysplastic syndromes
Phase III drugs:
AMG 531 - Immune thrombocytopenic purpura (an autoimmune bleeding disorder)
Darbepoetin alfa - Cardiovascular disease in patients with chronic kidney disease and type 2 diabetes
Darbepoetin alfa - Anemia in heart failure
Denosumab - Bone loss induced by hormone ablation therapy for breast cancer or prostate cancer
Denosumab - Postmenopausal osteoporosis
Denosumab - Prevention of cancer-related bone damage
Denosumab - Prevention of bone metastases
Cinacalcet HCI - Cardiovascular disease in patients with secondary hyperparathyroidism and chronic kidney disease undergoing maintenance dialysis
Panitumumab - First- and second-line colorectal cancer
[Source: FierceBiotech]
» 2007 Edition of the European Commission's Report of R&D Spending from PharmaGazette
The 2007 edition of the European Commission's annual report of research and development spending places Pfizer Inc. at the top of the heap outspending all other industries.Pharmaceuticals and biotechnology became the top R&D spenders beating ou... [Read More]
Tracked on: December 12, 2007 11:28 AM | Permalink to Trackback